Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Brii Biosciences Limited (BRIBF)
Beijing, CN
Brii Biosciences Limited, established in 2017 and headquartered in Beijing, China, is dedicated to advancing therapeutic solutions for infectious diseases and disorders affecting the central nervous system. Their diverse pipeline includes BRII-778 and BRII-732, both progressing through Phase I clinical trials for HIV patients. For Hepatitis B (HBV), they are evaluating BRII-179 and BRII-835 in a combined Phase 2 study; BRII-179 also stands as a recombinant protein-based HBV immunotherapeutic in Phase 1b/2a, while BRII-835 has completed Phase 2 for chronic HBV patients. Additionally, the Amubarvimab/romlusevimab combination therapy is under development for COVID-19. In the CNS arena, BRII-296 targets postpartum depression (PPD) and BRII-297 addresses various depressive disorders. Their anti-infective portfolio features BRII-636, BRII-672, and BRII-693, designed to combat multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections, alongside BRII-658 for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -17.43% | -17.43% | -35.41% | -16.77% | -40.23% | -62.95% | -94.35% | -94.35% | -94.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%-63.7% Q4'25: +8.6% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+57.1% ★ Q4'25: -580.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,983.4% Q4'25: -599.6% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-1,632.6% Q4'25: -1,184.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-75.6% Q4'25: -213.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-1.2% ★ Q4'25: -1.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q4'25: -0.01× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
51.63M
est: 160.84M (-67.9%)
|
617.0K
est: 109.56M (-99.4%)
|
49.94M
est: -77.47M (+164.5%)
|
18.12M
est: 28.29M (-35.9%)
|
310.26M
310.26M – 310.26M
+996.7% YoY
|
434.38M
434.38M – 434.38M
+40.0% YoY
|
2.16B
2.16B – 2.16B
+397.6% YoY
|
5.24M
5.24M – 5.24M
-99.8% YoY
|
| EBITDA |
-503.58M
est: -160.84M (-213.1%)
|
-168.20M
est: -109.56M (-53.5%)
|
-401.61M
est: 77.47M (-618.4%)
|
-290.31M
est: -28.29M (-926.2%)
|
-310.26M
-310.26M – -310.26M
-996.7% YoY
|
-434.38M
-434.38M – -434.38M
-40.0% YoY
|
-2.16B
-2.16B – -2.16B
-397.6% YoY
|
-5.24M
-5.24M – -5.24M
+99.8% YoY
|
| EBIT |
-513.85M
est: -160.84M (-219.5%)
|
-183.88M
est: -109.56M (-67.8%)
|
-403.85M
est: 77.47M (-621.3%)
|
-295.91M
est: -28.29M (-946.0%)
|
-310.26M
-310.26M – -310.26M
-996.7% YoY
|
-434.38M
-434.38M – -434.38M
-40.0% YoY
|
-2.16B
-2.16B – -2.16B
-397.6% YoY
|
-5.24M
-5.24M – -5.24M
+99.8% YoY
|
| Net Income |
-484.31M
est: -588.00M (+17.6%)
|
-174.83M
est: -910.79M (+80.8%)
|
-508.16M
est: -425.75M (-19.4%)
|
-216.88M
est: -187.62M (-15.6%)
|
-320.12M
-320.12M – -320.12M
-70.6% YoY
|
-312.67M
-312.67M – -312.67M
+2.3% YoY
|
-245.67M
-245.67M – -245.67M
+21.4% YoY
|
-238.23M
-238.23M – -238.23M
+3.0% YoY
|
| SGA |
80.33M
est: 3.21B (-97.5%)
|
57.10M
est: 2.18B (-97.4%)
|
203.94M
est: -1.62B (+112.6%)
|
101.68M
est: 592.16M (-82.8%)
|
6.49B
6.49B – 6.49B
+996.7% YoY
|
9.09B
9.09B – 9.09B
+40.0% YoY
|
45.24B
45.24B – 45.24B
+397.6% YoY
|
109.64M
109.64M – 109.64M
-99.8% YoY
|
| EPS |
-0.67
est: -0.81 (+16.8%)
|
-0.24
est: -1.25 (+80.8%)
|
-0.70
est: -0.59 (-18.7%)
|
-0.30
est: -0.26 (-15.4%)
|
-0.44
-0.44 – -0.44
-70.6% YoY
|
-0.43
-0.43 – -0.43
+2.3% YoY
|
-0.34
-0.34 – -0.34
+21.4% YoY
|
-0.33
-0.33 – -0.33
+3.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhi Hong | Co-founder, Executive Chairman of the Board & Chief Executive Officer | 1M | — |
| Ankang Li | COO, Joint Secretary & Executive Director | 809.9K | — |
| David Margolis | Chief Medical Officer | — | — |
| Eleanor de Groot | Chief Technology Officer | — | — |
| Haifeng Cao | Head of China Development | — | male |
| Karen Del Barrio Neuendorff | Chief People Officer & Head of Human Resources | — | female |
| Qing Zhu | Head of Pre-clinical Sciences and Translational Research | — | — |
| Sarah Qiu | Associate Director of Investor Relations | — | — |
| Susannah Cantrell | Chief Business Officer | — | — |
| Wing Tsz FCIS | Joint Company Secretary | — | female |
| Brian Alvin Johns | Chief Scientific Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BRIBF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
